Prasanth Puthanveetil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Prasanth Puthanveetil has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Daniel Rafferty
Midwestern University Chicago, College of Osteopathic Medicine, Downers Grove, Illinois, USA
3 shared publications- Cole Cochran
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
2 shared publications - Jennifer Choi
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
2 shared publications - Katelyn Martin
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
2 shared publications - Patrick Keefe
Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
2 shared publications Akanksh Shetty
Midwestern University
1 shared publication
Latest Publications
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 330 (4) , H1239-H1240
NAV3 as a novel and master regulator of cardiac fibrosis
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 330 (4) , H1239-H1240
NAV3 as a novel and master regulator of cardiac fibrosis
- Open Access
Diet, Inflammation, and Metabolic Complications
Inflammation is mostly categorized into sterile and nonsterile inflammation
Open AccessDiet, Inflammation, and Metabolic Complications
Inflammation is mostly categorized into sterile and nonsterile inflammation
- 1 October 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (10) , 594-595
A novel locus and HbA1c: tracing pathophysiological links beyond diabetes
- 1 October 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (10) , 594-595
A novel locus and HbA1c: tracing pathophysiological links beyond diabetes
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 328 (6) , G791-G800
Liver bypass in the development of pathogen-associated pulmonary vascular disease: contribution of mesocaval and portosystemic shunts
Portosystemic and mesocaval shunts are aberrant vascular connections that bypass hepatic detoxification process, directly linking the portal to the systemic circulation. These shunts, whether congenital or acquired, might play a pivotal role in the pathogenesis of systemic inflammatory diseases, such as schistosomiasis-associated pulmonary hypertension (Sch-PH) by facilitating the dissemination of pathogen-derived eggs and antigens from the gut and mesentery into the lungs. Beyond the translocation of Schistosoma mansoni eggs, emerging evidence implicates that gut-lung microbiome dysbiosis contributes to the development of pulmonary hypertension (PH) in the preclinical animal model of Sch-PH. Sch-PH emerges as a chronic complication of schistosomiasis and evolves silently, progressively increasing the mean pulmonary arterial pressure and vascular resistance, leading to right heart hypertrophy, failure, and significant morbidity and mortality. Chronic schistosomiasis is often linked to the development of portal hypertension, which significantly contributes to the formation of the porto/mesocaval shunt as a compensatory response that can have far-reaching implications on pulmonary vascular physiology. In addition, portal hypertension compromises the integrity of the intestinal barrier, exacerbating peritoneal and mesenteric inflammation, potentially facilitating microbial and metabolite entrance into the systemic circulation. This article briefly discusses the mechanisms by which porto/mesocaval shunts contribute to PH, especially Group I PH, focusing on the interplay between portosystemic shunting, microbial translocation, and systemic dissemination of proinflammatory metabolites.
- 1 June 2025
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 328 (6) , G791-G800
Liver bypass in the development of pathogen-associated pulmonary vascular disease: contribution of mesocaval and portosystemic shunts
Portosystemic and mesocaval shunts are aberrant vascular connections that bypass hepatic detoxification process, directly linking the portal to the systemic circulation. These shunts, whether congenital or acquired, might play a pivotal role in the pathogenesis of systemic inflammatory diseases, such as schistosomiasis-associated pulmonary hypertension (Sch-PH) by facilitating the dissemination of pathogen-derived eggs and antigens from the gut and mesentery into the lungs. Beyond the translocation of Schistosoma mansoni eggs, emerging evidence implicates that gut-lung microbiome dysbiosis contributes to the development of pulmonary hypertension (PH) in the preclinical animal model of Sch-PH. Sch-PH emerges as a chronic complication of schistosomiasis and evolves silently, progressively increasing the mean pulmonary arterial pressure and vascular resistance, leading to right heart hypertrophy, failure, and significant morbidity and mortality. Chronic schistosomiasis is often linked to the development of portal hypertension, which significantly contributes to the formation of the porto/mesocaval shunt as a compensatory response that can have far-reaching implications on pulmonary vascular physiology. In addition, portal hypertension compromises the integrity of the intestinal barrier, exacerbating peritoneal and mesenteric inflammation, potentially facilitating microbial and metabolite entrance into the systemic circulation. This article briefly discusses the mechanisms by which porto/mesocaval shunts contribute to PH, especially Group I PH, focusing on the interplay between portosystemic shunting, microbial translocation, and systemic dissemination of proinflammatory metabolites.
- Open Access
Compare and Contrast of the Cellular Actions of Related Flavonoids, Apigenin and Chrysin
In this review, we provide an evidence-based approach to determine the cellular and systemic actions of two structurally similar flavonoids, apigenin and chrysin. We have clearly evaluated and charted the overlapping and diverging properties of these two sister flavonoids. Based on two separate Omics-based approaches by our group and independent reports from others, the cholesterol-lowering properties have been revealed. In addition, the prevention of uric acid biosynthesis and enhancement of ketogenesis have also been quite evident in these two flavonoids. Along with these overlapping functions, apigenin and chrysin have also demonstrated unique properties that allow them to stand out from each other. Chrysin has demonstrated abilities like downregulating alanine metabolism and pyrimidine synthesis, which could be helpful in metabolic diseases like cancer. In contrast, apigenin has demonstrated anti-oxidant and anti-inflammatory properties by enhancing endogenous anti-inflammatory lipids and upregulating vasoprotective metabolites, which could be beneficial for cardiovascular, renal, and cerebrovascular complications. Further validation studies using in vivo and translational approaches could provide us with better clarity regarding the use of these agents therapeutically and to treat a combination or pool of metabolic diseases.
Open AccessCompare and Contrast of the Cellular Actions of Related Flavonoids, Apigenin and Chrysin
In this review, we provide an evidence-based approach to determine the cellular and systemic actions of two structurally similar flavonoids, apigenin and chrysin. We have clearly evaluated and charted the overlapping and diverging properties of these two sister flavonoids. Based on two separate Omics-based approaches by our group and independent reports from others, the cholesterol-lowering properties have been revealed. In addition, the prevention of uric acid biosynthesis and enhancement of ketogenesis have also been quite evident in these two flavonoids. Along with these overlapping functions, apigenin and chrysin have also demonstrated unique properties that allow them to stand out from each other. Chrysin has demonstrated abilities like downregulating alanine metabolism and pyrimidine synthesis, which could be helpful in metabolic diseases like cancer. In contrast, apigenin has demonstrated anti-oxidant and anti-inflammatory properties by enhancing endogenous anti-inflammatory lipids and upregulating vasoprotective metabolites, which could be beneficial for cardiovascular, renal, and cerebrovascular complications. Further validation studies using in vivo and translational approaches could provide us with better clarity regarding the use of these agents therapeutically and to treat a combination or pool of metabolic diseases.
- Open Access
- 31 May 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (6) , 320
Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases
Polyglutamine diseases comprise a cluster of genetic disorders involving neurodegeneration and movement disabilities. In polyglutamine diseases, the target proteins become aberrated due to polyglutamine repeat formation. These aberrant proteins form the root cause of associated complications. The metabolic regulation during polyglutamine diseases is not well studied and needs more attention. We have brought to light the significance of regulating glutamine metabolism during polyglutamine diseases, which could help in decreasing the neuronal damage associated with excess glutamate and nucleotide generation. Most polyglutamine diseases are accompanied by symptoms that occur due to excess glutamate and nucleotide accumulation. Along with a dysregulated glutamine metabolism, the Nicotinamide adenine dinucleotide (NAD+) levels drop down, and, under these conditions, NAD+ supplementation is the only achievable strategy. NAD+ is a major co-factor in the glutamine metabolic pathway, and it helps in maintaining neuronal homeostasis. Thus, strategies to decrease excess glutamate and nucleotide generation, as well as channelizing glutamine toward the generation of ATP and the maintenance of NAD+ homeostasis, could aid in neuronal health. Along with understanding the metabolic dysregulation that occurs during polyglutamine diseases, we have also focused on potential therapeutic strategies that could provide direct benefits or could restore metabolic homeostasis. Our review will shed light into unique metabolic causes and into ideal therapeutic strategies for treating complications associated with polyglutamine diseases.
- 31 May 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (6) , 320
Open AccessAltered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases
Polyglutamine diseases comprise a cluster of genetic disorders involving neurodegeneration and movement disabilities. In polyglutamine diseases, the target proteins become aberrated due to polyglutamine repeat formation. These aberrant proteins form the root cause of associated complications. The metabolic regulation during polyglutamine diseases is not well studied and needs more attention. We have brought to light the significance of regulating glutamine metabolism during polyglutamine diseases, which could help in decreasing the neuronal damage associated with excess glutamate and nucleotide generation. Most polyglutamine diseases are accompanied by symptoms that occur due to excess glutamate and nucleotide accumulation. Along with a dysregulated glutamine metabolism, the Nicotinamide adenine dinucleotide (NAD+) levels drop down, and, under these conditions, NAD+ supplementation is the only achievable strategy. NAD+ is a major co-factor in the glutamine metabolic pathway, and it helps in maintaining neuronal homeostasis. Thus, strategies to decrease excess glutamate and nucleotide generation, as well as channelizing glutamine toward the generation of ATP and the maintenance of NAD+ homeostasis, could aid in neuronal health. Along with understanding the metabolic dysregulation that occurs during polyglutamine diseases, we have also focused on potential therapeutic strategies that could provide direct benefits or could restore metabolic homeostasis. Our review will shed light into unique metabolic causes and into ideal therapeutic strategies for treating complications associated with polyglutamine diseases.
- Open Access
- 20 November 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1326266
Editorial: Global excellence in cardiovascular and smooth muscle pharmacology: north and Central America
Editorial: Global excellence in cardiovascular and smooth muscle pharmacology: north and Central America
- 20 November 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1326266
Open AccessEditorial: Global excellence in cardiovascular and smooth muscle pharmacology: north and Central America
Editorial: Global excellence in cardiovascular and smooth muscle pharmacology: north and Central America
- Open Access
- 17 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4066
Untargeted Metabolomics Based Prediction of Therapeutic Potential for Apigenin and Chrysin
The prominent flavonoids apigenin and chrysin have been demonstrated to have systemic benefits. Our previous work was first to establish the impact of apigenin and chrysin on cellular transcriptome. In the current study, we have revealed the ability of apigenin and chrysin to alter the cellular metabolome based on our untargeted metabolomics. Based on our metabolomics data, both these structurally related flavonoids demonstrate diverging and converging properties. Apigenin demonstrated the potential to possess anti-inflammatory and vasorelaxant properties through the upregulation of intermediate metabolites of alpha-linolenic acid and linoleic acid pathways. Chrysin, on the other hand, exhibited abilities to inhibit protein and pyrimidine synthesis along with downregulation of gluconeogenesis pathways based on the altered metabolites detected. Chrysin-mediated metabolite changes are mostly due to its ability to modulate L-alanine metabolism and the urea cycle. On the other hand, both the flavonoids also demonstrated converging properties. Apigenin and chrysin were able to downregulate metabolites involved in cholesterol biosynthesis and uric acid synthesis, namely 7-dehydrocholesterol and xanthosine, respectively. This work will provide understanding regarding the diverse therapeutic potential of these naturally occurring flavonoids and help us in curbing an array of metabolic complications.
- 17 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4066
Open AccessUntargeted Metabolomics Based Prediction of Therapeutic Potential for Apigenin and Chrysin
The prominent flavonoids apigenin and chrysin have been demonstrated to have systemic benefits. Our previous work was first to establish the impact of apigenin and chrysin on cellular transcriptome. In the current study, we have revealed the ability of apigenin and chrysin to alter the cellular metabolome based on our untargeted metabolomics. Based on our metabolomics data, both these structurally related flavonoids demonstrate diverging and converging properties. Apigenin demonstrated the potential to possess anti-inflammatory and vasorelaxant properties through the upregulation of intermediate metabolites of alpha-linolenic acid and linoleic acid pathways. Chrysin, on the other hand, exhibited abilities to inhibit protein and pyrimidine synthesis along with downregulation of gluconeogenesis pathways based on the altered metabolites detected. Chrysin-mediated metabolite changes are mostly due to its ability to modulate L-alanine metabolism and the urea cycle. On the other hand, both the flavonoids also demonstrated converging properties. Apigenin and chrysin were able to downregulate metabolites involved in cholesterol biosynthesis and uric acid synthesis, namely 7-dehydrocholesterol and xanthosine, respectively. This work will provide understanding regarding the diverse therapeutic potential of these naturally occurring flavonoids and help us in curbing an array of metabolic complications.
- Open Access
- 16 February 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (2) , 374
Metabolic Activation of PARP as a SARS-CoV-2 Therapeutic Target—Is It a Bait for the Virus or the Best Deal We Could Ever Make with the Virus? Is AMBICA the Potential Cure?
The COVID-19 pandemic has had a great impact on global health and is an economic burden. Even with vaccines and anti-viral medications we are still scrambling to get a balance. In this perspective, we have shed light upon an extremely feasible approach by which we can control the SARS-CoV-2 infection and the associated complications, bringing some solace to this ongoing turmoil. We are providing some insights regarding an ideal agent which could prevent SARS-CoV-2 multiplication. If we could identify an agent which is an activator of metabolism and is also bioactive, we could prevent corona activation (AMBICA). Some naturally occurring lipid molecules best fit this identity as an agent which has the capacity to replenish our host cells, specifically immune cells, with ATP. It could also act as a source for providing a substrate for host cell PARP family members for MARylation and PARylation processes, leading to manipulation of the viral macro domain function, resulting in curbing the virulence and propagation of SARS-CoV-2. Identification of the right lipid molecule or combination of lipid molecules will fulfill the criteria. This perspective has focused on a unique angle of host-pathogen interaction and will open up a new dimension in treating COVID-19 infection.
- 16 February 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (2) , 374
Open AccessMetabolic Activation of PARP as a SARS-CoV-2 Therapeutic Target—Is It a Bait for the Virus or the Best Deal We Could Ever Make with the Virus? Is AMBICA the Potential Cure?
The COVID-19 pandemic has had a great impact on global health and is an economic burden. Even with vaccines and anti-viral medications we are still scrambling to get a balance. In this perspective, we have shed light upon an extremely feasible approach by which we can control the SARS-CoV-2 infection and the associated complications, bringing some solace to this ongoing turmoil. We are providing some insights regarding an ideal agent which could prevent SARS-CoV-2 multiplication. If we could identify an agent which is an activator of metabolism and is also bioactive, we could prevent corona activation (AMBICA). Some naturally occurring lipid molecules best fit this identity as an agent which has the capacity to replenish our host cells, specifically immune cells, with ATP. It could also act as a source for providing a substrate for host cell PARP family members for MARylation and PARylation processes, leading to manipulation of the viral macro domain function, resulting in curbing the virulence and propagation of SARS-CoV-2. Identification of the right lipid molecule or combination of lipid molecules will fulfill the criteria. This perspective has focused on a unique angle of host-pathogen interaction and will open up a new dimension in treating COVID-19 infection.
- Open Access
- 1 January 2023
- Published by Bioscientifica in Redox Experimental Medicine
- Vol. 2023 (1)
Untargeted metabolomics reveal sex-specific and non-specific redox-modulating metabolites in kidneys following binge drinking
Binge drinking is a growing health concern among all age groups. The ability of individuals to handle ethanol in their systems differs not due to differences in enzyme expression but also due to other factors. Vital organs including brain, liver, heart and kidneys are at high risk following repeated exposure to high concentrations of ethanol from binge drinking. The impact of chronic binge drinking on kidneys is not well studied. Using a mouse model of chronic binge drinking, we have identified major metabolic alterations that could set the stage for detrimental effects in the kidneys of male and female mice. We have deciphered that even though there are pathway overlaps, the different sexes exhibited unique and divergent metabolic pathway dysregulations as per the metabolite panels following binge drinking. We have reported that binge drinking could negatively influence renal redox homeostasis in both sexes through regulation of different metabolite clusters. In male mice by downregulation of pantothenic acid and riboflavin synthesis, and female mice by upregulation of α-aminoadipic acid and formyl kynurenine level. Interestingly, uric acid biosynthesis pathway has been upregulated independent of the sex specific effects, portraying the significance of uric acid as a potential marker for binge drinking induced injury in both the sexes. Thus, by altering renal metabolome binge drinking sets the stage for renal damage by disturbing renal redox balance. Our data has high translational potential and will aid in finding ideal therapeutics in a sex-specific manner for subjects exposed to binge drinking induced renal injury.
- 1 January 2023
- Published by Bioscientifica in Redox Experimental Medicine
- Vol. 2023 (1)
Open AccessUntargeted metabolomics reveal sex-specific and non-specific redox-modulating metabolites in kidneys following binge drinking
Binge drinking is a growing health concern among all age groups. The ability of individuals to handle ethanol in their systems differs not due to differences in enzyme expression but also due to other factors. Vital organs including brain, liver, heart and kidneys are at high risk following repeated exposure to high concentrations of ethanol from binge drinking. The impact of chronic binge drinking on kidneys is not well studied. Using a mouse model of chronic binge drinking, we have identified major metabolic alterations that could set the stage for detrimental effects in the kidneys of male and female mice. We have deciphered that even though there are pathway overlaps, the different sexes exhibited unique and divergent metabolic pathway dysregulations as per the metabolite panels following binge drinking. We have reported that binge drinking could negatively influence renal redox homeostasis in both sexes through regulation of different metabolite clusters. In male mice by downregulation of pantothenic acid and riboflavin synthesis, and female mice by upregulation of α-aminoadipic acid and formyl kynurenine level. Interestingly, uric acid biosynthesis pathway has been upregulated independent of the sex specific effects, portraying the significance of uric acid as a potential marker for binge drinking induced injury in both the sexes. Thus, by altering renal metabolome binge drinking sets the stage for renal damage by disturbing renal redox balance. Our data has high translational potential and will aid in finding ideal therapeutics in a sex-specific manner for subjects exposed to binge drinking induced renal injury.